argenx

ISIN US04016X1019

 | 

WKN A2H9WD

 

Overview

Description

argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals Netherlands

Financials

Key metrics

Market capitalisation, EUR 21,307.29 m
EPS, EUR -
P/B ratio 7.70
P/E ratio -
Dividend yield 0.00%

Income statement (2023)

Revenue, EUR 1,136.08 m
Net income, EUR -273.34 m
Profit margin -24.06%

What ETF is argenx in?

There are 17 ETFs which contain argenx. All of these ETFs are listed in the table below. The ETF with the largest weighting of argenx is the First Trust NYSE Arca Biotechnology UCITS ETF Acc.
ETF Weight Investment focus Holdings TER Fund size (in m EUR) Return 1Y
Amundi Prime Global UCITS ETF DR (D) 0.03%
Equity
World
1,475 0.05% 671 +21.62%
Xtrackers World Net Zero Pathway Paris Aligned UCITS ETF 1C 0.06%
Equity
World
Social/Environmental
Climate Change
1,129 0.19% 25 +20.40%
First Trust NYSE Arca Biotechnology UCITS ETF Acc 3.47%
Equity
United States
Health Care
Biotech
30 0.60% 6 -4.84%
Invesco Nasdaq Next Generation 100 UCITS ETF Acc 0.88%
Equity
United States
Technology
104 0.25% 33 +8.76%
Amundi Prime Europe UCITS ETF DR (D) 0.20%
Equity
Europe
445 0.05% 52 +10.64%
L&G Gerd Kommer Multifactor Equity UCITS ETF USD Distributing 0.03%
Equity
World
Multi-Factor Strategy
2,875 0.50% 34 -
Xtrackers EMU Net Zero Pathway Paris Aligned UCITS ETF 1C 0.59%
Equity
Europe
Social/Environmental
Climate Change
162 0.15% 17 +12.03%
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 1.26%
Equity
United States
Health Care
Biotech
224 0.35% 41 +5.72%
L&G Gerd Kommer Multifactor Equity UCITS ETF USD Accumulating 0.03%
Equity
World
Multi-Factor Strategy
2,875 0.50% 156 -
iShares Nasdaq US Biotechnology UCITS ETF 1.26%
Equity
United States
Health Care
Biotech
224 0.35% 407 +5.69%
L&G Global Equity UCITS ETF 0.04%
Equity
World
Social/Environmental
1,241 0.10% 81 +22.13%
L&G Europe ex UK Equity UCITS ETF 0.27%
Equity
Europe
Social/Environmental
348 0.10% 260 +13.53%
Amundi Prime Eurozone UCITS ETF DR (C) 0.40%
Equity
Europe
213 0.05% 60 +13.54%
Amundi Prime Eurozone UCITS ETF DR (D) 0.40%
Equity
Europe
213 0.05% 42 +13.35%
Xtrackers Europe Net Zero Pathway Paris Aligned UCITS ETF 1C 0.30%
Equity
Europe
Social/Environmental
Climate Change
339 0.15% 5 +10.36%
Amundi Prime Europe UCITS ETF DR (C) 0.20%
Equity
Europe
445 0.05% 29 +10.79%
Amundi Prime Global UCITS ETF DR (C) 0.03%
Equity
World
1,475 0.05% 283 +21.76%
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.